Pharmacokinetic-Pharmacodynamic Target Attainment Analysis to Support VL-2397 Dose Selection for a Phase 2 Trial in Patients with Invasive Aspergillosis

BACKGROUND: VL-2397 is a novel antifungal agent in clinical development for treatment of invasive aspergillosis (IA). The analysis objectives were to: 1) develop a population PK model using data from a Phase 1 trial in healthy adult volunteers, 2) define the PK-PD driver of efficacy in a mouse model...

Descripción completa

Detalles Bibliográficos
Autores principales: Rubino, Christopher M, Smith, Larry R, Mammen, Mammen P, Hopkins, Andrew M, Lakota, Elizabeth A, Sullivan, Sean M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2017
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5631219/
http://dx.doi.org/10.1093/ofid/ofx163.1211

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5631219/
http://dx.doi.org/10.1093/ofid/ofx163.1211

Ejemplares similares